research reports and media, page-3342

know that this has nothing to do with OA or PAR, but shows one way a company partners with another for sales and distribution.

With FDA decision one month away, Provention partners with Sanofi

on US marketing for type 1 diabetes drug.

Though its FDA decision is one month away, Provention Bio has already begun its commercial efforts for its type 1 diabetes drug — and it’s now working with Sanofi.

Sanofi has signed on as Provention’s potential commercial partner in the US if teplizumab, Provention’s antibody treatment for delaying the onset of symptomatic type 1 diabetes, gets approved in November. Sanofi will invest $35 million upon approval at a 40% premium per share.

Sanofi also dropped $20 million to get first dibs on negotiations for global rights to teplizumab in type 1 diabetes.

Full story here:

With FDA decision one month away, Provention partners with Sanofi on US marketing for type 1 diabetes drug

With FDA decision one month away, Provention partners with Sanofi on US ... Though its FDA decision is one month away, Provention Bio has already begun its commercial efforts for its type ...

One of many possibilities.